跳至主要内容
临床试验/NCT02982824
NCT02982824已完成不适用

Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy: A Pilot Study

Ain Shams University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2016年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
IQ improvement

研究概览

简要总结

Effect of oral magnesium sulfate (Mg) supplementation will be studied. Children with drug resistant idiopathic epilepsy following up in Pediatric Neurology Clinic, Ain Shams University, will be randomized to either Mg add-on treatment group or anti-epileptic drugs AEDs alone. Serum magnesium, seizure control and Intelligent quotation (IQ) will be done at base line and after 6 months of treatment.

详细描述

The Aim of this work was to study the effect of Magnesium as add on therapy on clinical seizure control in drug resistant idiopathic epilepsy and IQ.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
6 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children with drug resistant idiopathic epilepsy

排除标准

  • Structural, Metabolic, Infectious and Unknown etiology epilepsy
  • Any neurological disease other than epilepsy
  • Any nutritional disorder
  • Any other systemic diseases (including Renal disease, Cardiac arrhythmia)
  • Drug intake other than antiepileptic drugs (AED)

研究组 & 干预措施

Magnesium add-on

Experimental

20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.

干预措施: Magnesium (Dietary Supplement)

Antiepileptic drugs only

Placebo Comparator

20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.

干预措施: Placebo - Concentrate (Drug)

结局指标

主要结局

IQ improvement

时间窗: 6-months

Change from base line IQ (Wechsler Intelligence Scale-Revised for Children and Adults)

Seizure control

时间窗: 6 months

Change from base line seizure frequency, severity (Chalfont scale) at 6 months.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sahar M.A. Hassanein, MD

Professor of Pediatrics and Head of Pediatric Neurology Unit, Children's

Ain Shams University

研究点 (1)

Loading locations...

相似试验